Modiodal (Modafinil)

Modafinil, the active ingredient in Modiodal, is a eugeroic (wakefulness‑promoting agent) presented as an oral tablet for oral use. It is indicated to reduce daytime sleepiness in adults with narcolepsy, obstructive sleep apnea‑related residual sleepiness, and shift work sleep disorder, helping improve alertness and functional performance.

GNH USA supplies Modiodal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modiodal (modafinil) promotes wakefulness in disorders characterized by excessive daytime sleepiness.

- Narcolepsy: reduces sudden sleep attacks and improves daytime alertness. - Obstructive sleep apnea‑related excessive daytime sleepiness: lessens residual sleepiness despite optimal apnea therapy. - Shift work sleep disorder: helps maintain alertness during scheduled work hours.

Modiodal may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate discomfort often reported during the first weeks of therapy. - Nausea: transient gastrointestinal upset that usually resolves with continued use. - Insomnia: difficulty falling or staying asleep, especially when taken later in the day. - Anxiety or nervousness: heightened sense of restlessness in some patients.

Serious or Rare Side Effects: - Severe skin reactions (e.g., Stevens‑Johnson syndrome): requires immediate medical attention. - Psychiatric events (e.g., mania, depression, hallucinations): monitor patients with pre‑existing mental health conditions. - Cardiovascular events (e.g., hypertension, arrhythmia): seek urgent care if chest pain or palpitations occur.

Before initiating Modiodal, clinicians should consider several safety measures.

- Assess cardiovascular status: evaluate blood pressure and heart disease history. - Avoid use in patients with known hypersensitivity to modafinil or its excipients. - Monitor for psychiatric symptoms: watch for new or worsening depression, mania, or psychosis. - Consider dose adjustment in hepatic impairment: reduced clearance may increase exposure. - Pregnancy and lactation: use only if the potential benefit outweighs the risk. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Modiodal can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise modafinil plasma levels. - CNS depressants (e.g., benzodiazepines): may diminish the wake‑promoting effect. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may lower modafinil concentrations and reduce effectiveness.

Moderate Interactions (Monitor Closely): - Oral contraceptives: modafinil may reduce hormonal contraceptive efficacy. - Antidepressants (especially SSRIs): increased risk of serotonin‑related adverse events. - Alcohol: may enhance central nervous system side effects such as dizziness or headache.